Navigation Links
Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.

SAN JOSE, Calif., March 9 /PRNewswire/ -- Teikoku Pharma USA Inc., the international specialty pharmaceutical company, announces that it has signed an exclusive worldwide (excluding Japan) licensing agreement with Eisai Co., Ltd. to develop and commercialize a new transdermal formulation of donepezil, a leading compound for the treatment of Alzheimer's disease in the world.

The transdermal formulation is a once-a-week patch that continuously delivers donepezil through the skin into the bloodstream. It will enable the number of doses to be reduced, make it easier to be used for patients with Alzheimer's disease who have difficulty in swallowing, and also reduce the burden of caregivers or family members when administering it to patients.

About Teikoku

Teikoku Pharma USA Inc. is a wholly-owned subsidiary of Teikoku Seiyaku Inc., a specialty pharmaceutical company that develops, and manufactures enhanced pharmaceutical products based on its transdermal drug delivery technologies. Teikoku focuses its efforts in two therapeutic areas; chronic and acute Pain and CNS. Teikoku's main product is Lidoderm(R) (lidocaine 5% patch) for PHN (post herpetic neuralgia) , in collaboration with Endo Pharmaceuticals in the US, Grunenthal GmBH in Europe, Mundipharma in South East Asia and SK Pharma for Korea.

Teikoku's commitment is to expand Trandermal technologies for the benefit of patients and partners. For more information, please visit

About Eisai

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, integrative oncology, and vascular/immunology reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. For more information, please visit .

SOURCE Teikoku Pharma USA Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. IDM Pharmas MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma
2. Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
3. Florida Emergency Room Costs Increased 25 Percent in the Last Year and May Lead to More Opportunity for Pharma Industry
4. Victory Pharma Announces $45 Million Equity Financing
5. Children's Hospital Central California and CVS/Pharmacy Wheelchair Fund Featured in "Extreme Makeover: Home Edition"
6. Email Fax Provider, EasyLink Services, Announces Prominent Bio-Pharma Signing
7. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
8. Merz Aesthetics, a Division of Merz Pharmaceuticals USA, Introduces a Universal Language of Aging for Use in Education, Research and Practice
9. CFO of Genesis Pharmaceuticals Gives Live Interview on Bloomberg TV Asia
10. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
11. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today ... owner, Somu now offers travelers, value and care based Travel Services, including exclusive ... as well as, cabin upgrades and special amenities such as, shore excursions, discounted ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer ... classically-influenced trailer titles work with any font, giving users limitless opportunities to stylize ...
(Date:11/25/2015)... ... 2015 , ... The holiday season is jam-packed with family ... of attendees is of the utmost importance. Whether you are cooking at home ... recipes a try this holiday season. , Turkey Croquettes ,     Ingredients: ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior ... (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil societies ... the opening of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like ... , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. ... OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... WILMINGTON, N.C. , Nov. 25, 2015 /PRNewswire/ ... announces the planned investment of at least $15.8 ... in Wilmington, NC . The ... services capacity to meet the growing demands of ... Wilmington site expansion will provide up ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan plc (NYSE: ... agreement with the New York State ... of the Sherman Act, and other statutes with the Attorney ... February 2014, to cease marketing and selling the now generic ... settlement, Allergan admits no liability, has released its counterclaims against ...
(Date:11/25/2015)... USP 800 applies to all healthcare ... pharmacy technicians, nurses, physicians, physician assistants, home healthcare ... covers all entities which store, prepare, transport, or ... institutions, patient treatment clinics, physicians, practice facilities, and ... --> What is the purpose of USP ...
Breaking Medicine Technology: